Aprea Therapeutics, Inc (APRE) insider trading
Every open-market stock purchase and sale by Aprea Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $181K over the last 12 months (7 buys).
- Last insider buy: Richard Peters (Director), $84.6K, 7 months ago.
Last 12 months: insiders bought $181K (7 buys) and sold $0 (0 sales). Last close $0.54 on Oct 22, 2026.
Recent APRE insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 16, 2026 | Bernd R. Seizinger (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Rifat Pamukcu (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Rifat Pamukcu (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Bernd R. Seizinger (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Marc Duey (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Marc Duey (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Jean-Pierre Bizzari (Director) | Bought (not open market) | — |
| Jun 16, 2026 | John B Henneman III (Director) | Bought (not open market) | — |
| Jun 16, 2026 | John B Henneman III (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Richard Peters (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Richard Peters (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Gabriela Gruia (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Gabriela Gruia (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Michael Grissinger (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Michael Grissinger (Director) | Bought (not open market) | — |
| Jun 16, 2026 | Jean-Pierre Bizzari (Director) | Bought (not open market) | — |
| Mar 31, 2026 | Richard Peters (Director) | Bought | $84.6K |
| Mar 31, 2026 | John P. Hamill (CFO) | Bought | $21.2K |
| Mar 12, 2026 | Oren Gilad (CEO) | Bought (not open market) | — |
| Mar 12, 2026 | John P. Hamill (CFO) | Bought (not open market) | — |
| Mar 12, 2026 | John P. Hamill (CFO) | Bought (not open market) | — |
| Mar 12, 2026 | Oren Gilad (CEO) | Bought (not open market) | — |
| Jan 30, 2026 | Oren Gilad (CEO) | Bought | $21.5K |
| Jan 30, 2026 | John P. Hamill (CFO) | Bought | $4.4K |
| Dec 10, 2025 | Marc Duey (Director) | Bought | $22.3K |
Who's trading APRE
- Bernd R. Seizinger, Director: other filings, last Jun 16, 2026
- Marc Duey, Director: bought $22.3K (1 buy), last Jun 16, 2026
- Rifat Pamukcu, Director: other filings, last Jun 16, 2026
- Richard Peters, Director: bought $84.6K (1 buy), last Jun 16, 2026
- Jean-Pierre Bizzari, Director: other filings, last Jun 16, 2026
- Michael Grissinger, Director: other filings, last Jun 16, 2026
- Gabriela Gruia, Director: other filings, last Jun 16, 2026
- John B Henneman III, Director: other filings, last Jun 16, 2026
- John P. Hamill, CFO: bought $30.7K (3 buys), last Mar 31, 2026
- Oren Gilad, CEO: bought $43.8K (2 buys), last Mar 12, 2026
Get free alerts when an insider at Aprea Therapeutics, Inc files a new trade →